Myasthenia Gravis – Propel

The PROPEL Study is testing an investigational treatment called IMVT-1402 to learn how it works in the body and if it is safe and effective for people with mild to severe gMG. Participants will receive IMVT-1402 or a placebo as a weekly injection, and continue taking their current MG medication(s), to see if it may help muscles get the signals they need to do their job.

Individuals may qualify for the study if they:

• Are 18 to 75 years of age
• Have been diagnosed with mild to severe generalized myasthenia gravis (gMG)
• Are being treated or have been treated with one or more medication for gMG
• Meet additional study criteria

Reimbursement for reasonable, out-of-pocket expenses for travel and accommodations may be available to qualified individuals.